Patents by Inventor Mitchell H. Sokoloff

Mitchell H. Sokoloff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to a tumor-associated surface antigen for delivery of diagnostic and therapeutic agents
    Publication number: 20040228860
    Abstract: The present invention relates to the treatment, inhibition and prevention of cancer by the administration of anti-C3b(i) antibodies. The invention also relates to the treatment, inhibition and prevention of cancer by the administration of IgM antibodies and/or complement components prior to the administration of anti-C3b(i) antibodies. The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.
    Type: Application
    Filed: November 21, 2003
    Publication date: November 18, 2004
    Applicant: The University of Virginia Patent Foundation
    Inventors: Ronald Taylor, Alessandra Nardin, William M. Sutherland, Mitchell H. Sokoloff, Leland Chung
  • Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
    Patent number: 6596712
    Abstract: A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. Synergistically effective amounts are preferred. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, doxorubicin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. Alternatively, the first treatment may be a treatment with one or more conventional anti-hormonal agents. As examples, the anti-hormonal agents may be a LHRH (luteinizing hormone releasing hormone) agonist or an anti-androgen such as flutamide, biclutamide, nilutamide, and luprolide. These conventional cancer treatments compounds and the squalamine may be administered by any suitable route.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: July 22, 2003
    Assignee: Genaera Corporation
    Inventors: Michael Zasloff, Jon Williams, Mitchell H. Sokoloff
  • Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
    Patent number: 6572856
    Abstract: The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies specific for C3b(i). The present invention also relates methods of treating and preventing cancer, viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more cancer cell antigens, viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 3, 2003
    Assignee: The University of Virginia Patent Foundation
    Inventors: Ronald Taylor, Alessandra Nardin, William M. Sutherland, Mitchell H. Sokoloff, Leland Chung
  • Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
    Publication number: 20010046521
    Abstract: A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. Synergistically effective amounts are preferred. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, doxorubicin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. Alternatively, the first treatment may be a treatment with one or more conventional anti-hormonal agents. As examples, the anti-hormonal agents may be a LHRH (luteinizing hormone releasing hormone) agonist or an anti-androgen such as flutamide, biclutamide, nilutamide, and luprolide. These conventional cancer treatments compounds and the squalamine may be administered by any suitable route.
    Type: Application
    Filed: March 12, 2001
    Publication date: November 29, 2001
    Inventors: Michael Zasloff, Jon Williams, Mitchell H. Sokoloff